[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fungal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fungal-disease":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,67,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390",false,"NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","ALL","18 Years","90 Years",{"count":20,"type":21},400,"ESTIMATED","30 Days","OBSERVATIONAL","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[26,27,28,29,30,31,32,33,34,35],"Pneumonia","Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[27,37,29,38,32,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2025-11-13",{"date":62,"type":21},"2031-11-13",{"name":64,"class":65},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":17,"enrollmentInfo":75,"targetDuration":77,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":66},"100620393","a-real-world-prospective-observational-study-on-the-efficacy-and-safety-of-l-ambliposomal-amphotericin-b-for-br--ifdbreakthrough-invasive-fungal-disease-in-children-and-adolescent-patients-with-hematological-malignancies-receiving-triazoles-or-echinocandins-prophylaxis-100620393","NCT07357038","A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis","A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB for br- IFD in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis","Inclusion Criteria:\n\n* The children and adolescent patients with hematological malignancy received echinocandin\u002Ftriazole for antifungal prophylaxis and diagnosed with br-IFD.\n\n  1. Age: from 1 month to 18 years old.\n  2. Diagnosed patients with hematological malignancy.\n  3. Received echinocandin\u002Ftriazole for antifungal prophylaxis at least 7 days.\n  4. Br-IFD is defined as a proven, probable, and possible IFD diagnosed at least 7 days after the start of primary antifungal prophylaxis and by 7 days from the end of primary antifungal prophylaxis. Definitions of proven, probable and possible IFD based on the EORTC\u002FMSG 2020 criteria.\n  5. ECOG-PS(Eastern Cooperative Oncology Group Performance Status): 0-2 points.\n  6. There are no organ dysfunction restrictions during the screening period that limit the use of this protocol.\n  7. The guardian understands the research and signs written informed consent form.\n\nExclusion Criteria:\n\n* (a) Received AmB formulation for prophylaxis or treatment within the past 30 days.\n\n  (b) Confirmed allergy\u002Frapid onset severe allergic reaction\u002Fintolerance to L-AmB (c) Has a history of other tumors and has received any treatment for this tumor within the past 3 years (d) HIV, active hepatitis B and active hepatitis C virus or syphilis infection (e) Suffering from mental illness or other conditions that prevent cooperation with research, treatment, and monitoring requirements (f) Serum creatinine level 2 times the upper limit of normal; Liver transaminase or alkaline phosphatase levels 5 times the upper limit of normal, bilirubin levels 3 times the upper limit of normal (g) Researchers believe that patients who are not suitable for inclusion","1 Month",{"count":76,"type":21},38,"12 Weeks","The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and adolescent patients with hematological malignancies receiving triazoles\u002Fechinocandins antifungal prophylaxis.\n\nThe main question it aims to answer is:\n\n1. Whether the L-AmB have the same efficacy in the treatment of br-IFD in Chinese children and adolescent with hematological malignancies who are receiving triazoles or echinocandins antifungal prophylaxis as in adults(compared with historical data)\n2. Whether L-AmB may have better renal safety in Chinese children and adolescent than in adults (compared with historical data).\n\nChinese children and adolescent with hematological malignancies will taking L-AmB as part of their regular medical care for br-IFD. The efficacy and safety data will be recorded.",[33],[81,82,83,84],"malignant hematological diseases","breakthrough","invasive fungal disease","liposomal amphotericin B","2026-01-15",{"date":87,"type":58},"2026-01-21",{"date":89,"type":58},"2025-09-30",{"date":91,"type":21},"2027-05-31",{"name":93,"class":65},"Institute of Hematology & Blood Diseases Hospital, China",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":66},"100590614","azole-susceptibility-and-resistance-mechanisms-surveys-in-pathogenic-fungi-by-the-carst-fungi-2023-2024-100590614","NCT06969703","Azole Susceptibility and Resistance Mechanisms Surveys in Pathogenic Fungi by the CARST-fungi (2023-2024)","Azole Susceptibility and Resistance Mechanisms Surveys in Pathogenic Fungi by the China Antifungal Resistance Surveillance Trial (CARST)-Fungi (2023-2024)","Inclusion Criteria:\n\n* fungal disease\n\nExclusion Criteria:\n\n* non-fungal disease",{"count":102,"type":21},30,"The China Antifungal Resistance Surveillance Trial (CARST-fungi) study, which has been starting in July 2019, is a multi-center, prospective, observational, and laboratory-based study of pathogenic fungal isolates causing IFDs. All fungal isolates recovered from clinical samples will be collected. For each episode of fungal isolation, the information including the patient's age, gender, the ward location, the time of sample collection, and specimen type will be collected. All isolates will be sent to the Research Center for Medical Mycology, Beijing, China, for further study including species identification and azole susceptibility testing. Azole-resistant mechanisms will be elucidated by gene sequencing or expression level assay for resistance-related genes.",[33],[106,107,108,109],"Azole susceptibility","pathogenic fungi","resistance mechanisms","Resistance Surveillance","NOT_YET_RECRUITING","2025-05-12",{"date":113,"type":58},"2025-05-14",{"date":115,"type":21},"2025-06-10",{"date":89,"type":21},{"name":118,"class":65},"Peking University First Hospital"]